350 rub
Journal Technologies of Living Systems №3 for 2015 г.
Article in number:
Insuline-like growth factor system. Part 2: breast cancer. Igf-system in disease progression. Targeted therapy
Keywords: IGF system insulin-like growth factor IGF breast cancer targeted therapy
Authors:
Yu.S. Timofeev - Physician of Clinical Laboratory Diagnostics, Clinical Biochemistry laboratory, Russian Cancer Research Center of N.N. Blokhin (Moscow). E-mail: timofeev_lab@mail.ru U.R. Mamedov - Ph. D. (Med.), Senior Research Scientist, Russian Canter Research Center of N.N. Blokhin O.I. Kostyleva - Ph. D. (Med.), Senior Research Scientist, Russian Canter Research Center of N.N. Blokhin А.V. Маslyaev - Oncologist, Russian Canter Research Center of N.N. Blokhin I.K. Vorotnikov - Dr. Sc. (Med.), Professor, Russian Canter Research Center of N.N. Blokhin E.S. Gershtein - Dr. Sc. (Biol.), Russian Canter Research Center of N.N. Blokhin
Abstract:
In this part of the survey we provides a data of the role of the IGF system in breast cancer and its impact on all stages of tumor development: the malignant cell transformation, tumor growth, local invasion, distant metastasis and resistance to treatment. IGF system has a significant influence on the clinical course and, therefore, and breast cancer progression. The review also describes the basic genetic mechanisms of destruction of IGF, which can lead to the for-mation of a malignant phenotype. In the final part of the review we enlighten the possible therapeutic strategies, which are based on inhibiting the activity of the system. IGFs, their receptors and IGFBPs play an important role in the process of malignant transformation, growth, invasion, angiogenesis and metastasis makes promising target-IGF system in tumor therapy.
Pages: 50-62
References

 

  1. Moschos S.J., Mantzoros C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications // Oncology. 2002. V. 64. P. 317-332.
  2. Werner H., Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action // Trends Endocrinol. Metab. 2006. V. 17(6). R. 236-242.
  3. Prueitt R.L., Boersma B.J., Howe T.M., Goodman J.E., Thomas D.D., Ying L., Pfiester C.M., Yfantis H.G., Cottrell J.R., Lee D.H., Remaley A.T., Hofseth L.J., Wink D.A., Ambs S. Inflammation and IGF-I activate the Akt pathway in breast cancer // Int. J. Cancer. 2007. V. 120(4). R. 796-805.
  4. Ciftci K., Su J., Trovitch P.B. Growth factors and chemotherapeutic modulation of breast cancer cells // J. Pharm. Pharmacol. 2003. V. 55(8). R. 1135-1141.
  5. Jameel J.K., Rao V.S., Cawkwell L., Drew P.J. Radioresistance in carcinoma of the breast // Breast. 2004. V. 13(6). R. 452-460.
  6. Sisci D., Surmacz E. Crosstalk between IGF signaling and steroid hormone receptors in breast cancer // Curr. Pharm. Des. 2007. V. 13(7). R. 705-717.
  7. Arnold J.T., Le H., McFann K.K., Blackman M.R. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells // Am. J. Physiol. Endocrinol. Metab. 2005. V. 288(3). R. 573-584.
  8. Zhang S., Li X., Burghardt R., Smith R. 3rd.,  Safe S.H. Role of estrogen receptor (ER) alpha in insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells // J. Mol. Endocrinol. 2005. V. 35(3). R. 433-447.
  9. Bradley L.M., Gierthy J.F., Pentecost B.T. Role of the insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line // J. Steroid Biochem. Mol. Biol. 2008. V. 109(1-2). R. 185-196.
  10. Ling Y., Maile L.A., Clemmons D.R. Tyrosine phosphorylation of the ß3-subunit of the Vß3 integrin is required for membrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor // Mol. Endocrinol. 2003. V. 17. P. 1824-1833.
  11. Bonanni B., Johansson H., Gandini S., et al. Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women // Breast Cancer Res. Treat. 2001. V. 69. № 1. P. 21-27.
  12. Eng-Wong J., Hursting S.D., Venzon D. et al. Effect of Raloxifene on Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Leptin in Premenopausal Women at High Risk for Developing Breast Cancer // Cancer Epidemiol. Biomarkers Prev. 2003. V. 12. P. 1468-1473.
  13. Ibrahim Y.H., Yee D. Insulin-like growth factor-I and breast cancer therapy // Clin. Cancer Res. 2005. V. 11. № 2 (Pt 2). P. 944s-950s.
  14. Samani A.A., Yakar S., LeRoith D. et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights // Endocr. Rev. 2007. V. 28. № 1. P. 20-47.
  15. Yakar S., Leroith D., Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models // Cytokine Growth Factor Rev. 2005. V. 16. P. 407-420.
  16. Ren Z., Shin A., Cai Q. Shu X.O., Gao Y.T., Zheng W. IGFBP3 mRNA expression in benign and malignant breast tumors // Breast Cancer Res. 2007. V. 9(1). R. 2
  17. Vestey S.B., Perks C.M., Sen Ch., Calder C.J., Holly J.M., Winters Z.E. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome // Breast Cancer Res. 2005. V. 7(1). R. 119-129.
  18. Johansson H., Baglietto L., Guerrieri-Gonzaga A., Bonanni B., Mariette F., Macis D., Serrano D., Sandri M.T., Decensi A. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer // Breast Cancer Res. Treat. 2004. V. 88(1). R. 63-73.
  19. Renehan A.G., Zwahlen M., Minder C., O-Dwyer S.T., Shalet S.M., Egger M. Insulin-like growth factor (IGF)-I, IGF binding proteinprotein-3, and cancer risk: systematic review and meta-regression analysis // Lancet. 2004. V. 363. R. 1346-1353.
  20. Singer C.F., Mogg M., Koestler W., Pacher M., Marton E., Kubista E., Schreiber M.Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions // Clin. Cancer Res. 2004. V. 10(12 Pt 1). R. 4003-4009.
  21. Baglietto L., English D.R., Hopper J.L., Morris H.A., Tilley W.D., Giles G.G. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer // Cancer Epidemiol. Biomarkers Prev. 2007. V. 16(4). R. 763-768.
  22. Pazaitou-Panayiotou K., Kelesidis T., Kelesidis I., Kaprara A., Blakeman J., Vainas I., Mpousoulegas A., Williams C.J., Mantzoros C. Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer // Eur. J. Endocrinol. 2007. V. 156(2). R. 187-194.
  23. Probst-Hensch N.M., Steiner J.H., Schraml P., Schraml P., Varga Z., Zürrer-Härdi U., Storz M., Korol D., Fehr M.K., Fink D., Pestalozzi B.C., Lütolf U.M., Theurillat J.P., Moch H. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity // Clin. Cancer Res. 2010. V. 16(3). R. 1025-1032.
  24. Zhang X., Yee D. Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer // Breast Cancer Res. 2000. V. 2(3). R. 170-175.
  25. Kahán Z., Gardi J., Nvári T. et al. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study // Int. J. Oncol. 2006. V. 29. № 1. P. 193-200.
  26. Campbell M.J., Woodside J.V., Secker-Walker J., et al. IGF status is altered by tamoxifen in patients with breast cancer // Mol. Pathol. 2001. V. 54. № 5. P. 307-310.
  27. Freedland S.J., Aronson W.J. Examining the Relationship Between Obesity and Prostate Cancer // Rev. Urol. 2004. V. 6. № 2. P.73-81.
  28. Da Silva B.B., Moita D.S., Pires C.G. et al. Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene // Int. Semin. Surg. Oncol. 2007. V. 4. P. 18.
  29. Masljaev A.V., Kostyleva O.I., Gershtejjn E.S., Ermilova V.D., Grickevich M.V., Portnojj S.M. Insulinopodobnye faktory rosta v syvorotke krovi bolnykh rakom molochnojj zhelezy // Voprosy biologicheskojj medicinskojj i farmacevticheskojj khimii. 2012. № 10. S. 16-20.
  30. Kostyleva O.I., Masljaev A.V., Ermilova V.D., Vysockaja I.V., Grickevich M.V., Ovchinnikova L.K., Portnojj S.M. Insulinopodobnye faktory rosta v syvorotke krovi bolnykh rakom molochnojj zhelezy // Molekuljarnaja medicina. 2014. № 1.S. 33-36.
  31. Gershtejjn E.S., Kushlinskijj N.E. Sovremennye predstavlenija o mekhanizmakh peredachi signalov faktorov rosta kak osnova ehffektivnojj molekuljarno-napravlennojj protivoopukholevojj terapii // Voprosy biologicheskojj medicinskojj i farmacevticheskojj khimii. 2007. № 1. S. 4-9.
  32. Cui H., Cruz-Correa M., Giardiello F.M., Hutcheon D.F., Kafonek D.R., Brandenburg S., Wu Y., He X., Powe N.R., Feinberg A.P. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk // Science. 2003. V. 299. P. 1753-1755.
  33. Armengol G., Knuutila S., Lluis F., Capella G., Miro R., Caballin M.R. DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma // Cancer Genet. Cyto. Genet. 2000. V. 116. P. 133-141.
  34. Bassi D.E., Fu J., Lopez de Cicco R., Klein-Szanto A.J. Proprotein convertases: «master switches» in the regulation of tumor growth and progression // Mol. Carcinog. 2005. V. 44. P. 151-161.
  35. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells // J. Biol. Chem. 2002. V. 277. P. 38205-38211.
  36. Hakomori S.Glycosylation defining cancer malignancy: new wine in an old bottle // Proc. Natl. Acad. Sci. USA. 2002. V. 99. P. 10231-10233.
  37. Sciacca L., Mineo R., Pandini G., Murabito A., Vigneri R., Belfiore A. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the Insulin receptor isoform A. // Oncogene. 2002. V. 21. P. 8240-8250.
  38. Chang Y.S., Wang L., Liu D., Mao L., Hong W.K., Khuri F.R., Lee H.Y. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer // Clin. Cancer Res. 2002. V. 8. P. 3669-3675.
  39. Kiepe D., Ciarmatori S., Hoeflich A., Wolf E., Tonshoff B. Insulin-like growth factor (IGF)-I stimulates cell proliferation and induces IGF binding protein (IGFBP)-3 and IGFBP-5 gene expression in cultured growth plate chondrocytes via distinct signaling pathways // Endocrinology. 2005. V. 146. P. 3096-310.
  40. Yi H.K., Kim S.Y., Hwang P.H., Kim C.Y., Yang D.H., Oh Y., Lee D.Y. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adeno-carcinoma cells // Biochem. Biophys. Res. Commun. 2005. V. 330. P. 760-767.
  41. Kalli K.R., Falowo O.I., Bale L.K., Zschunke M.A., Roche P.C., Conover C.A. Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling // Endocrinology. 2002. V. 143. P. 3259-3267.
  42. Boissan M., Beurel E., Wendum D., Rey C., Lecluse Y., Housset C., Lacombe M.L., Desbois-Mouthon C. Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma // Am. J. Pathol. 2005. V. 167. P. 869-877.
  43. Lee Y.I., Han Y.J., Lee S.Y., Park S.K., Park Y.J., Moon H.B., Shin J.H., Lee J.H.Activation of insulin-like growth factor II signaling by mutant type p53: physiological implications for potentiation of IGF-II signaling by p53 mutant 249 // Mol. Cell Endocrinol. 2003. V. 203. P. 51-63.
  44. Hwang P.H., Kim S.Y., Lee J.C., Kim S.J., Yi H.K., Lee D.Y. PTEN/MMAC1 enhances the growth inhibition by anticancer drugs with downregulation of IGF-II expression in gastric cancer cells // Exp. Mol. Med. 2005. V. 37. P. 391-398.
  45. Li J., Sahagian G.G. Demonstration of tumor suppression by mannose 6-phosphate/insulin-like growth factor 2 receptor // Oncogene. 2004. V. 23. P. 9359-9368.
  46. Guerreiro A.S., Boller D., Doepfner K.T., Arcaro A. IGF-IR: potential role in antitumor agents // Drug News Perspect. 2006. V. 19. № 5. P. 261-272.
  47. Hartog H., Wesseling J., Boezen H.M. et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future // Eur. J. Cancer. 2007. V. 43. № 13. P. 1895-1904.
  48. Larsson O., Girnita A., Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer // Br. J. Cancer. 2007. V. 96 (Suppl.) P. R2-6.
  49. Levitt R.J., Buckley J., Blouin M.J., et al. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression // Biochem. Biophys. Res. Commun. 2004. V. 316. № 2. P. 421-428.
  50. Camirand A., Zakikhani M., Young F., et al. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells // Breast Cancer Res. 2005. V. 7. № 4. P. R570-R579.
  51. Paz K., Hadari Y.R. Targeted therapy of the insulin-like growth factor-1 receptor in cancer // Comb. Chem. High Throughput Screen. 2008. V. 11. № 1. P. 62-69.
  52. Fürstenberger G., Senn E., Morant R., et al. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer // Breast. 2006. V. 15. № 1. P. 64-68.